Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops

The emergence of low molecular weight kinase inhibitors as “targeted” drugs has led to remarkable advances in the treatment of cancer patients. The clinical benefits of these tumor therapies, however, vary widely in patient populations and with duration of treatment. Intrinsic and acquired resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: von Manstein, Viktoria, Yang, Chul Min, Richter, Diane, Delis, Natalia, Vafaizadeh, Vida, Groner, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095943/
https://www.ncbi.nlm.nih.gov/pubmed/25045345
http://dx.doi.org/10.2174/1574362409666140206221931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095943/
https://www.ncbi.nlm.nih.gov/pubmed/25045345
http://dx.doi.org/10.2174/1574362409666140206221931

Ejemplares similares